logo-loader

Northland Capital Partners View on the City - Techfinancials (LON:TECH); Motif Bio (LON:MTFB)

no_picture_pai.jpg

SECTOR: HEALTHCARE; SOFTWARE & SERVICES

NORTHLAND VIEW
 Motif announced it will be presenting at the following two conferences in March 2018.
 Superbugs & Superdrugs 2018 (March 19-20, London, UK): David Huang, Chief Medical Officer, will give a presentation on iclaprim, the Company’s lead antibiotic drug candidate, at 12:10pm on Tuesday, March 20th. Link to conference site: here.
 Oppenheimer 28th Annual Healthcare Conference (March 20-21, New York, NY): Graham Lumsden, Chief Executive Officer, will give a corporate presentation at 11:30am on Wednesday, March 21st. Link to conference website here.
These two conferences provide a platform for the Company to meet with leaders from pharmaceutical companies, academia, regulatory agencies and investors. In 2017, Motif completed two Phase 3 trials testing iclaprim, its lead antibiotic candidate, in acute bacterial skin and skin structure infection (ABSSSI).
The Company is focusing on submitting a new drug application (NDA) for the use of iclaprim in ABSSSI to the US FDA in the first quarter of 2018. With a lead asset and two successful Phase 3 trials completed, Northland views Motif as significantly undervalued.

COMPANY DESCRIPTION
Clinical-stage biopharmaceutical company specialising in the development of novel antibiotics.

 

NORTHLAND VIEW
TechFinancials reported completion of its CEDEX token pre-sale event announced on 16th March, with sales of 25m CEDEX tokens, at 1ETH=900 CEDEX tokens, as planned.
 Subsequently, the main sale started on 17th March at 10:00am and is scheduled to run to 17th April, or until the hard cap (total issuance of coin created) of 50m CEDEX tokens sold is achieved.
 TechFinancials CEO, Asaf Lahav, commented: "We are excited to announce that the CEDEX pre-sale event has completed, using TechFinancials' technology, which has been developed over the past six months since we entered the blockchain market. Whilst offering CEDEX our proprietary technology, we are pleased to have been able to provide the company with a 360° solution in order to meet its operational needs."

As noted on 16th March, progress updates on the token sale are available at www.cedex.com, currently showing a total of 25,705,052 tokens sold amounting to a total contribution of US$20.211m.

COMPANY DESCRIPTION
TechFinancials is a leading technology provider to binary options brokers.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Emmerson Resources discusses recent diamond drilling...

Emmerson Resources Ltd (ASX:ERM) managing director and CEO Rob Bills updates Proactive on the first diamond drilling activities at the Whatling Hill Project in NSW.  A 1,500-metre reverse circulation (RC) and diamond drilling program is targeting an interpreted porphyry copper-gold...

5 hours, 30 minutes ago

2 min read